Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Express Scripts
Medtronic
Johnson and Johnson

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR ZONEGRAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zonegran

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00056576 ↗ Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Completed Eisai Inc. Phase 3 2002-02-01 The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
NCT00154076 ↗ A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies Completed Eisai Korea Inc. Phase 4 2005-09-01 To assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828 ↗ Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization Terminated Eisai GmbH Phase 4 2005-05-01 Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50 mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control assessments are performed at the beginning of the study and at the end of the prospective baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first, second, and third treatment week, and at the end of week six, the patient is additionally contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all control visits, and at the end of the study.
NCT00203450 ↗ Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Eisai Inc. Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00203450 ↗ Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed Tuscaloosa Research & Education Advancement Corporation Phase 4 2003-05-01 The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.
NCT00215592 ↗ Open Label, Zonegran (Zonisamide) In Partial Onset Seizures Completed Eisai Limited Phase 4 2005-10-01 To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.
NCT00221442 ↗ Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed Eisai Inc. Phase 3 2005-08-01 The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zonegran

Condition Name

Condition Name for Zonegran
Intervention Trials
Epilepsy 10
Healthy 6
Alcohol Dependence 4
Alcoholism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zonegran
Intervention Trials
Seizures 9
Epilepsy 9
Alcoholism 7
Deafness 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zonegran

Trials by Country

Trials by Country for Zonegran
Location Trials
United States 38
Australia 11
Germany 8
Hungary 6
Poland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zonegran
Location Trials
Ohio 4
Connecticut 4
Massachusetts 3
North Carolina 3
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zonegran

Clinical Trial Phase

Clinical Trial Phase for Zonegran
Clinical Trial Phase Trials
Phase 4 7
Phase 3 15
Phase 2 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zonegran
Clinical Trial Phase Trials
Completed 25
Terminated 7
Withdrawn 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zonegran

Sponsor Name

Sponsor Name for Zonegran
Sponsor Trials
Eisai Inc. 9
Eisai Limited 5
United States Department of Defense 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zonegran
Sponsor Trials
Industry 29
Other 27
U.S. Fed 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.